VistaGen's stem cell technology platform is based on proprietary and licensed technologies for controlling the differentiation of human pluripotent stem cells (hPSCs) and producing the multiple types of mature, non-transformed, functional, adult human cells that we use, or plan to use, to reproduce complex human biology and disease and assess, in-vitro, the potential therapeutic benefits and safety risks of new chemical entities (NCEs).
We use our hPSC-derived cardiomyocytes (human heart cells) in CardioSafe 3D™, our novel, customized in-vitro bioassay system for predicting potential cardiotoxicity of drug rescue NCEs. We believe CardioSafe 3D is more comprehensive and clinically predictive than the hERG assay, currently the only in-vitro cardiac safety assay required by FDA guidelines, and that CardioSafe 3D offers a new paradigm for evaluating and predicting potential heart toxicity of drug rescue NCEs early in development, long before costly, high-risk human clinical trials.
Stem cell technology-based regenerative medicine (RM) has the potential to transform healthcare worldwide over the next decade by providing new approaches for treating fundamental mechanisms of disease. We currently intend to leverage our stem cell technology platform and our expertise in the differentiation of human pluripotent stem cells and development of customized human cell assays to develop novel human disease models for discovery of small molecule drugs with regenerative and therapeutic potential. In addition, among our key objectives will be to collaborate with others to advance potential RM opportunities for cell therapy involving blood, bone, cartilage, heart and/or liver cells.